beta

GERN

Geron Corp.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.

Market Cap: 1.15 Billion

Primary Exchange: NASDAQ

Website: http://www.geron.com/

Shares Outstanding: 546 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.5981162617296283

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1629 trading days

From: 2018-09-25 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud